At ADA 2026, Boehringer Ingelheim reported that its obesity drug survodutide (licensed from Zealand Pharma) was linked to meaningful discontinuation rates in a phase 3 program. Separate conference materials emphasized tolerability positioning, including weight-loss magnitude and analysis of fat versus lean mass loss. Conference commentary cited that 19% of phase 3 participants quit survodutide over side effects. Boehringer’s follow-up messaging at the meetings then highlighted “targeted” weight loss, reporting MRI sub-study findings with larger reductions in visceral fat versus placebo, and asserting that total tissue mass changes suggest fat-driven weight loss predominates. The debate is likely to remain centered on tolerability acceptability relative to class peers and on whether the risk-benefit profile supports broad, long-term chronic use. Investors and payers will be watching for whether discontinuation signals translate into label constraints or necessitate narrower prescribing.